 PBCAR0191 is being explored in a phase 12 study in patients with relapsedrefractory Non-Hodgkin Lymphoma and rr B-cell Acute Lymphoblastic Leukemia. Data updates from PBCAR0191, PBCAR19B for non-Hodgkins Lymphoma and PBCAR269A for multiple myeloma are expected before end of 2022. 